All In Biotech

NDA 018333 · Abbvie

Carafate

Sucralfate · Oral · Aluminum Complex

NovelPriority review

Last checked: Nov 20, 2026Latest source record: Mar 4, 2013 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1981

Oct 30, 1981

Approved uses

2

Original approval plus efficacy supplements

Registered trials

26

4 Phase 3, 2 recruiting

FAERS reports

24,155

16,587 serious, 2,328 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Sep 2, 2026.

INDICATIONS AND USAGE Sucralfate is indicated in: • Short-term treatment (up to 8 weeks) of active duodenal ulcer. While healing with sucralfate may occur during the first week or two, treatment should be continued for 4 to 8 weeks unless healing has been demonstrated by x-ray or endoscopic examination. • Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • May 11, 1990 Supplement 9 · Efficacy
  • Oct 30, 1981 Original approval · Type 1 - New Molecular Entity · priority review
1 products under this application
  • CARAFATE · SUCRALFATE 1GM · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Sucralfate" as an intervention, any sponsor and status, largest first.

All 26 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • nausea2,389
  • fatigue1,831
  • diarrhoea1,787
  • pain1,543
  • headache1,453
  • vomiting1,433
  • off label use1,386
  • dyspnoea1,383
  • drug ineffective1,359
  • dizziness1,095
  • abdominal pain1,035
  • weight decreased1,031

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004252
2005266
2006251
2007265
2008324
2009405
2010543
2011660
2012880
2013727
2014841
20151,422
20161,829
20171,577
20181,878
20192,058
20201,851
20211,461
20221,358
20231,407
20241,322
20251,509
20261,064

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Carafate (Sucralfate)

2024 spending

$1.3M

Beneficiaries

1,372

2,941 claims

Per beneficiary

$917

$1.24 per unit

View as table
YearSpending
2020$28,700,306
2021$6,334,080
2022$3,052,062
2023$2,290,698
2024$1,257,911

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 534 on PubMed

Sponsor: AbbVie

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.